OptiBiotix Health Plc

OptiBiotix Health Plc is a biotechnology company founded in 2006, headquartered in the United Kingdom. The company specializes in developing compounds that modify the human microbiome to prevent and manage human diseases. Their focus is on discovering and developing microbial strains, compounds, and formulations to modulate the human microbiome for the prevention and management of metabolic diseases such as obesity, cholesterol and lipid distribution, and diabetes.

OptiBiotix has a pipeline of microbiome modulators with the potential to impact lipid and cholesterol management, energy harvest, and appetite suppression. This pipeline is supported by the proprietary OptiScreen® and OptiBiotic® platform technologies, designed to identify metabolic pathways and compounds that can bring potential health benefits to individuals. These platforms have applications across a wide range of human diseases, making the company's approach versatile and adaptable.

The latest investment in OptiBiotix Health Plc amounted to £1.35M, which was made in the form of a Post-IPO Equity investment on 25 March 2024. The investor involved in this round of funding was Graham Myers.

With its focus on leveraging the human microbiome to develop innovative solutions for metabolic diseases, OptiBiotix is positioned as a promising player in the biotechnology and healthcare industries, offering the potential for significant advancements in human health and well-being.